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Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade
(ICB) antibodies, have demonstrated the capacity of the immune system to fight
cancer in a number of malignancies such as melanoma and lung cancer. The
numbers, localization and phenotypes of tumor-infiltrating lymphocytes (TIL) are not
only predictive of response to immunotherapy but also key modulators of disease
progression. In this review, we focus on TIL profiling in cutaneous melanoma using
histopathological approaches and highlight the observed prognostic value of the primary
TIL subsets. The quantification of TIL in formalin-fixed tumor samples ranges from
visual scoring of lymphocytic infiltrates in H&E to multiplex immunohistochemistry
and immunofluorescence followed by enumeration using image analysis software.
Nevertheless, TIL enumeration in the current literature primarily relies upon single marker
immunohistochemistry analyses of major lymphocyte subsets such as conventional T
cells (CD3, CD4, CD8), regulatory T cells (FOXP3) and B cells (CD20). We review key
studies in the literature on associations between TIL subsets and patient survival. We
also cover recent findings with respect to the existence of ectopic lymphoid aggregates
found in the TME which are termed tertiary lymphoid structures (TLS) and are generally
a positive prognostic feature. In addition to their prognostic significance, the existence
of various TIL sub-populations has also been reported to predict a patient’s response
to ICB. Thus, the literature on the predictive potential of TIL subsets in melanoma
patients receiving ICB has also been discussed. Finally, we describe recently developed
state-of-the-art profiling approaches for tumor infiltrating immune cells such as digital
pathology scoring algorithms (e.g., Immunoscore) and multiplex proteomics-based
immunophenotyping platforms (e.g., imaging mass cytometry). Translating these novel
technologies have the potential to revolutionize tumor immunopathology leading to
altering our current understanding of cancer immunology and dramatically improving
outcomes for patients.
Keywords: melanoma, tumor infiltrating lymphocyte, prognostic marker, tumor immunology and
microenvironment, immunotherapy, tertiary lymphoid structure
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INTRODUCTION
Over the past two decades, tumor immunotherapy has
demonstrated remarkable clinical success for a number of
different types of cancers (1, 2). While a large variety of drugs are
currently in clinical trials for tumor immunotherapy, the overall
therapeutic aims of these agents are to disrupt or counteract
tumor-mediated immunosuppression (3, 4). The most clinically
effective immunotherapies to date are monoclonal antibodies
targeting the checkpoint molecules CTLA-4 (cytotoxic T
lymphocyte-associated protein 4) and PD-1 (programmed cell
death protein 1) as well as its ligand PD-L1 (4–6). While there is
significant variability in the response rates to these drugs based
on the tumor type, a recent pooled analysis demonstrated an
average objective response rate (ORR) of 14% for anti-CTLA-4
and 33% for anti-PD-1 mAbs (7). In a separate meta-analysis of
results from phase III trials with ICB, it was shown that patients
treated with ICB were over 2 times more likely to experience
durable clinical responses compared to patients in the control
(non-ICB) arms of these trials (8). Thus, tumor immunotherapy
is established as a key therapeutic approach for the clinical
treatment of cancer.
The successful response to immunotherapies is predicated
on the immunological composition or “immune contexture” of
the tumor microenvironment (TME) (9–11). Furthermore, the
increased presence of certain cell types has also been shown to be
associated with enhanced survival in patients with various forms
of cancer (10, 12). These observations are in accordance with the
canonical understanding that a healthy immune system regularly
eliminates pro-tumorigenic cells and can mount responses to
established cancers which eventually escape immune control and
progress, a concept currently known as “cancer immunoediting”
(13, 14). The processes through which the immune system both
restricts and promotes tumorigenesis remain a key focus of
current immunology research (14, 15). As such, an assessment of
tumor infiltrating immune cells, in particular tumor infiltrating
lymphocytes (TIL) is of critical importance in biomedical
research as well as clinical pathology (10, 12, 16).
Cutaneous melanoma is the most lethal form of skin cancer
(17). The incidence of cutaneous melanoma continues to rise
in Europe and 5-year survival rates remain low (<30%) despite
the advent of tumor immunotherapies (18). In both preclinical
and clinical studies on melanoma, examination of TIL and
various TIL subsets by histopathologists has yielded several
biological insights in tumor immunology (10, 19). For over
three decades, a number of clinical centers have demonstrated
the therapeutic potential of adoptive TIL transfer in melanoma
(2). However, the technical challenges and costs associated with
this method have limited a wider application of this approach
and the development of transgenic T cell receptor bearing T
cells remains an important field of immunotherapy research.
Nevertheless, as the mechanistic and prognostic relevance of
various TIL subsets in cancer remains a key avenue of research,
it is imperative to understand current approaches to TIL
profiling and their association with patient clinical outcomes
(12). While techniques, such as multi-color flow cytometry and
mass cytometry (CyTOF) currently permit high dimensional
immunophenotyping of human tissues, these procedures require
tissue dissociation which leads to loss of crucial spatial and
morphological information (20). Thus, clinical pathology on
fixed tissue sections remains the gold standard for examining
the TME in situ. Generally, routine histopathology is performed
on whole tissue sections but in recent years, a large number
of investigational studies have started to use tissue microarrays
(TMA) for biomarker discovery and immunological or molecular
profiling in cancer research (12, 21).
In this review, we explore the prognostic relevance of TIL
pattern profiling enumerating various lymphocyte subsets. We
also examine their predictive value for ICB treatment. Moreover,
novel algorithms for histological assessment of tumors such as the
ImmunoScore method as well as machine-learning based image
analysis will be discussed. Finally, novel methodologies for high-
throughput immunophenotyping of tumors will be described.
Collectively, this work provides a scientific primer on TIL
subsets in melanoma and highlights novel immunophenotyping
techniques which harbor significant promise for advancing our
understanding of tumor-infiltrating lymphocytes.
PROFILING OF TIL IN CUTANEOUS
MELANOMA
TIL Assessment in H&E
Following the first characterization of TIL in melanoma by Clark
in 1969, multiple groups reported that lymphocyte infiltration
correlated with improved survival in melanoma patients (22).
While research has shown that immune cell subsets are highly
heterogeneous within human cancers, enumerating TIL using
H&E provides an important insight on the TME in a number
of cancer types (12, 23). Histologically, the location of the
immune infiltrate may be described as intratumoral, stromal
or peritumoral (12, 24). Intratumoral immune cells are located
directly within the malignant “nest” of tumor cells (12). The
stromal region is composed of blood vessels, connective tissue
and various immune cells (24). The outer border of the tumor
is known as the invasive front (24). The term peritumoral
may be thus applied to the cells around the invasive front,
in the stroma or in adjacent non-involved tissue (12, 24).
Currently, there is no single unified approach for assessing
overall immune infiltrates in H&E stained tissue in solid tumors.
Both intratumoral and peritumoral lymphocytes may be assessed
and analyzed for correlation to various clinical parameters
(12). However, it is relevant to note that a vast majority of
pathological analyses are currently performed using digitized
whole slide images (25, 26). This allows for high resolution
images, dynamic zooming and panning capabilities and permits
the images to be analyzed using image analysis softwares (25).
Generally, in cutaneous melanoma, TIL scoring is performed for
round inflammatory cells excluding polymorphonuclear cells in
the intratumoral region only (27). The biological and clinical
significance of examining intratumoral versus peritumoral TIL
has been discussed elsewhere (12, 28, 29). Furthermore, while
a majority of studies examining TIL have been performed
using primary melanoma tumors, some groups have also
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studied the prognostic value of examining TIL in metastatic
samples (30–32).
There are presently two primary strategies for scoring TIL in
H&E stained melanoma tissue, the system devised by Clark and
colleagues and the approach promoted by the Melanoma Institute
Australia (MIA) (12, 33, 34). The Clark scoring system was first
reported in 1989 and defines three distinct TIL patterns as absent,
non-brisk and brisk (Figure 1) (23, 35). Absent indicates when no
TIL are present or they do not infiltrate the tumor (27, 35). Non-
brisk denotes one or more scattered foci of lymphocytes (22, 35).
Brisk describes a diffuse infiltration of lymphocytes throughout
the tumorigenic vertical growth phase (VGP) or along the base of
the tumor (23, 35, 36). Clemente et al. further divided the scoring
of brisk TIL patterns into peripheral (along the tumor base)
or diffuse (infiltrating the entire invasive portion of the tumor)
(23, 37). Generally, perivascular lymphocytes and lymphocytes
in regions of fibrosis are not included in the scoring (23). The
Clark system remains in wide usage due to its reproducibility,
ease of application and strong interobserver agreement (23, 38).
The MIA scoring system is based on the density (mild, moderate
or marked) and distribution of TIL (focal, multifocal, or diffuse
across the entire tumor) in the dermis (23, 34). The MIA ordinal
score (0–3) is defined as follows: grade 0; TIL absent, grade
1; a mild multifocal or a mild/moderate focal infiltrate, grade
2; a moderate or marked multifocal, a marked focal or a mild
diffuse TIL pattern, grade 3; a moderate or marked diffuse
infiltrate (34).
Both the Clark and MIA scoring systems have demonstrated
that increased TIL levels are associated with improved prognosis.
In the aforementioned report by Clark et al., the authors
studied 8-year survival in over 200 patients with exhibiting
distinct histologic subtypes of primary cutaneous melanoma
(35). The 8-year survival rate in patients with absent TIL was
59, 75% in patients with non-brisk TIL patterns and 88% in
patients with brisk TIL (35). As a further demonstration of
the biological relevance of TIL scoring, the absence of TIL
as defined by Clark, was associated with increased sentinel
lymph node (SLN) metastases (39). SLN status remains the
most important independent prognostic factor in melanoma
(40). In 2012, Azimi et al. utilized the MIA scoring system to
show that TIL grade in the primary cutaneous melanoma was
inversely associated with SLN positivity and was independently
associated with disease-specific survival (DSS) (34). Thus, there
is ample evidence to demonstrate that the presence of TIL
is associated with an enhanced host response to the tumor
and therefore is associated with improved patient outcomes.
A recently reported meta-analysis of 41 published studies on
TIL in melanoma showed that simply the presence of TIL
was significantly associated with improved overall survival (OS)
(33). A majority of the studies included in this meta-analysis
were performed on primary cutaneous melanoma (33). The
authors of this report demonstrated that brisk TIL patterns
were associated with improved prognosis with respect to OS,
recurrence free survival (RFS) and DSS (33). Together, these
findings indicate that the presence of lymphocytes in the tumor
mass is representative of a host immune response to the cancer
and thus it is generally associated with positive clinical outcomes.
Given the utility of H&E assessment of TIL, the International
Immuno-Oncology Biomarker Working Group (IOBWG) has
proposed a more standardized approach for TIL assessment
(41). However, this approach requires validation in melanoma
and other solid tumors in order to determine its viability
for prognosis. Despite the effective use of TIL scoring as a
prognostic tool in melanoma, the immune cells infiltrating a
tumor are phenotypically and functionally diverse (42). The
TME for most cancers is highly heterogeneous and through
histological assessment, three major categories of immune
infiltration have been identified (43, 44). Broadly, tumors can
be classified as those with T cell-inflamed (hot) and non-T
cell-inflamed (cold) TME (Figure 2) (44). Profiling of these
subtypes has shown that T cell-inflamed tumors contain high
density of CD8+ TIL, expression of PD-L1, increased IFNγ
signaling and a high mutational burden (43, 44). Non-T cell-
inflamed tumors generally have an immune-excluded TME
with a peripheral accumulation of T cells which are unable
to enter the tumor mass as a result of immunosuppressive
FIGURE 1 | Schematic representation of the three canonical TIL infiltration patterns in cutaneous melanoma. (A) Absent: No presence of lymphocytes in the tumor
or no infiltration within the tumor itself. (B) Non-brisk: One or multiple scattered foci of lymphocytes. (C) Brisk: Diffuse infiltration of lymphocytes throughout the
tumorigenic vertical growth phase or along the tumor base.
Frontiers in Immunology | www.frontiersin.org 3 September 2020 | Volume 11 | Article 2105
fimmu-11-02105 September 8, 2020 Time: 18:21 # 4
Maibach et al. Emerging Advances in TIL Profiling
FIGURE 2 | H&E and CD3 immunostaining can be utilized to distinguish T cell-inflamed and non-inflamed tumor microenvironments. Representative images from
malignant melanoma samples comparing (A) a tumor with mild, focal lymphocytic infiltration with (B) few T cells compared to (C) a tumor exhibiting dense TIL
patterns and (D) a high frequency of T cells. Scale bar = 100 µm.
myeloid cells or stroma (43). Alternately, cold tumors may
also represent an immune-ignored phenotype with minimal or
absent T cell infiltration with highly proliferative tumor cells,
lack of PD-L1 expression and a low mutational burden (43,
44). The classifications described here are general categories
derived from histopathological analyses of tumor tissue (43).
The roles of stromal cells, mutational burden and tumor-
infiltrating immune cells in driving the phenotype of the TME
are still not well described and require further elucidation
(43, 45). As such, IHC for the detection and enumeration
of major lymphocyte subsets in the tumor and determining
their correlation to patient survival or response to treatment,
is also a crucial approach for clinical and pre-clinical cancer
research (10, 45).
Assessment of TIL Subsets via IHC
Tumor infiltrating immune cells are heterogeneous in both
phenotype and function and form an interactive network
with other immune cells and non-immune components of
the TME (10, 42). Due to advances in monoclonal antibody
production, it is presently possible to detect numerous leukocyte
subsets in histopathology tissue samples using both IHC and
immunofluorescence (IF) (10, 20, 46). However, a majority
of studies use antibodies targeted to key surface markers to
broadly identify major TIL subsets in cancer such as CD20
(B cells), CD3 (T cells), CD4 & CD8 (T cells) and FOXP3
(Regulatory T cells or Treg) (12, 33, 47). While tumor infiltrating
CD8+ T cells have been shown to be associated with positive
outcomes and FOXP3+ Treg are usually associated with negative
outcomes, there is tremendous heterogeneity in the results
of IHC-based detection and enumeration of TIL subsets in
cancer (10, 12, 30). However, there is no single approach for
quantifying immune cells in tumor tissue. Thus, certain studies
perform semi-quantitative (e.g., low/high or 0–3) grading by
visual examination (48, 49), or using image analysis software to
determine percentage of pixels positive for IHC staining (50).
The Clark grading system of absent, non-brisk and brisk for
TIL in H&E tissue has also been applied to tissue with stains
for lymphocyte markers such as CD8 (51). On the other hand,
the total cells positive for a specific marker (e.g., CD3) are
enumerated using visual assessment or digital image analysis
software (31, 52, 53). Given the variety of techniques utilized to
score TIL and TIL subsets in cancer between studies, conflicting
results regarding their prognostic relevance in cancer are to be
expected. However, recent advances in machine learning image
analysis algorithms are promising in their capacity to unify and
automate digital pathology, thereby yielding more consistent
results (54, 55).
In the context of melanoma, studies have shown that
while the presence of intratumoral lymphocytes is generally
a positive prognostic factor, inspecting individual populations
using markers such as CD3 or CD8, or activated T cells, may
yield conflicting results in smaller cohorts of patients (30, 33).
In a recent review, Fridman et al. combined data from 200
previously published studies in various cancer types to obtain a
comprehensive view of the prognostic value of major immune
cells subsets (10). A key limitation in the case of melanoma
versus other tumors such as colorectal cancer and breast cancer
is the relative scarcity of studies examining lymphocyte subsets
and their association with prognosis (10). Nevertheless, it has
been observed that while T cells (CD3+, CD8+, CD4+) and
B cells (CD20+) are associated with better patient outcomes,
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TABLE 1 | Overview of TIL subset detection via IHC, their canonical functions in the tumor microenvironment and association with patient survival.
TIL subset Primary identification marker† Canonical anti-tumor
function(s)
Association with patient survival‡ References
Cytotoxic T lymphocyte CD8 Direct cytotoxicity to tumor
cells. Production of IFNy
Positive (31, 32, 67, 68)
No association (51)
Helper T lymphocyte CD4 Production of pro-inflammatory
cytokines. Direct cytotoxicity to
tumor cells.
Positive (32, 68)
No association (31)
Regulatory T lymphocyte FOXP3 Direct and indirect suppression
of effector lymphocytes. Inhibit
APC functions.
No association (31, 32, 93)
B lymphocyte CD20 Production of anti-tumor
antibodies. Antigen
presentation.
Positive association (31, 102)
No association (168)
Negative association (104)
†Accepted as primary markers for the following cell types in the scientific literature. ‡Only statistically significant associations between density of each TIL subset and
patient outcomes (OS, RFS, DSS, PFS) were included.
FOXP3+ Treg are associated with worse prognosis (Table 1)
(10, 12, 30, 56). In this section, we will review the known
roles of major TIL subsets in tumor immunity as well as novel
methods which might improve and refine immunophenotyping
of these subsets in cancer. Finally, it is important to note that
while TIL immunophenotyping primarily relies upon detection
of immune cell specific protein markers, a number of studies
have also performed gene expression profiling of tumor tissue
to detect immune cell specific transcripts (57). These approaches
can currently be complemented by examining immune cell
specific transcripts in bulk tumor RNA sequencing datasets which
are publicly available at The Cancer Genome Atlas (TCGA)
(58). In addition to assessing individual genes, a number of
“immune cell deconvolution” algorithms have attempted to
estimate the relative abundance of tumor-infiltrating leukocytes
based on unique gene signatures for each cell type (59).
Furthermore, high or low expression of these signatures may
be compared with survival data which is available in TCGA,
to predict the prognostic value of various leukocyte subsets
(60). While gene expression signatures can provide evidence
of a tumor’s immune profile, ultimately the presence of these
cells in the TME must be validated through flow cytometry
or histopathology.
CD8+ TIL
CD8+ T cells play a central role in the adaptive immune response
to cancer (61–63). Activated CD8+ T cells are termed cytotoxic
T lymphocytes (CTL) as they are capable of directly recognizing
and killing malignant and infected cells (61, 63). While multiple
immune cells can exhibit tumoricidal activity including natural
killer (NK) cells and macrophages, CTL are the primary
immune cells capable of controlling tumor growth and mediating
responses to cancer immunotherapies (62–64). The primary anti-
tumor activities of CTL involves their killing of target cells via
the exocytosis of cytotoxic granules containing perforin and
granzymes as well as the production of cytokines such as IFNγ
and tumor necrosis factor (TNF) (62, 63). Recent evidence
shows that a subset of conventional dendritic cells (cDC),
cDC1 are essential for the recruitment and priming of CD8+
T cells in the TME (65). As described in the aforementioned
conceptual framework of cancer immunoediting, after a period
of initial control by T cells, the tumor is able to evade the
immune attack and promote an immunosuppressive TME (14,
61). On the other hand, chronic antigen exposure such as in
the context of chronic viremia and cancer, leads to a state
termed T cell exhaustion marked by loss of effector functions, a
sustained expression of inhibitory surface receptors (e.g., PD-1)
and distinct transcriptional profiles (66). Therefore, the diverse
phenotypes and functional profiles of CD8+ TIL in the TME
complicate the interpretation of histological studies on these cells
in tumor tissues (12, 30).
In an early report CD8+ TIL levels in primary cutaneous
melanoma tumors were found to be associated with increased
survival in a cohort of 47 patients (67). By stratifying the patients
based on CD8+ T cell density, the 5-year OS for the high,
moderate and low-density groups was observed to be 78, 44, and
25%, respectively (67). However, in a larger cohort of over 180
primary cutaneous melanoma samples in 2011, they found no
correlation between CD8+ TIL and patient survival (51). Thus,
these studies demonstrate the complexity of determining the
prognostic relevance of CD8+ TIL using immunohistochemistry.
In addition to primary tumors, a number of studies have also
examined the TIL profiles of metastatic lesions. These reports
have shown that an increased density of CD8+ T cells in
metastatic melanoma lesions (Stage III and IV) is positively
associated with survival (31, 32). As previously discussed, CD8+
TIL secrete a number of functional molecules and express a
wide variety of surface markers (62). Therefore, some studies
have investigated the use of labeling activation markers or
effector molecules in addition to labeling CD8 when studying
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the prognostic significance of CD8+ TIL. In a cohort of primary
melanoma tumors (Stage II), it was shown that the presence of
TIL positive for the CD8+ T cell effector molecule Granzyme B
(GZMB) were associated with longer progression-free survival
(PFS) and OS (68). Dual IF labeling confirmed that GZMB+
TIL were also positive for CD8 (68). Further research on the
functional status of T cells in the TME has revealed a number
of biologically relevant surface markers which may assist in
examining the prognostic value of CD8+ TIL in melanoma. Flow
cytometric analyses of intratumoral CD8+ T cells in metastatic
lymph nodes (mLN) have shown that the expression of the
chemokine receptors CXCR3 and CCR9, as well as the c-type
lectin, NKG2D, on CD8+ TIL correlates with improved clinical
outcomes in cutaneous melanoma (69). An important distinction
in the TME is that between lymphocytes which are tumor-specific
(i.e., recognize tumor antigens) and bystander TIL (70). Using
a multiplexed tetramer and mass cytometry based approach,
surface expressed ectonucleotidase CD39 was identified as a
marker to distinguish tumor-specific CD8+ TIL in lung and
colorectal cancers (70). In this report, the authors found that
bystander TIL express inhibitory receptors such as PD-1 and
TIGIT (T cell immunoreceptor with Ig and ITIM domains)
which were previously reported to distinguish tumor-specific
“exhausted” TIL (70, 71). While advanced immunophenotyping
technologies have demonstrated the diversity of CD8+ TIL in
the TME, the prognostic utility of labeling additional markers
on CD8+ TIL such as TIGIT, CD39 or NKG2D in clinical
and research pathology has yet to be determined. Nevertheless,
assessment of CD8+ T cells in the TME remains one of
the key readouts for intratumoral immune activation when
assessing disease prognosis or determining successful response to
immunotherapies (12, 72).
CD4+ TIL
Similar to CD8+ T cells, CD4+ T helper (TH) cells exhibit
tremendous diversity in phenotype and function (73). Moreover,
CD4+ T cells are essential for cancer immunity via mechanisms
that have been recently reviewed (73, 74). CD4+ T cells can
directly kill tumor cells via cytolytic mechanisms or produce
cytokines such as IFNγ which promote anti-tumor immune
responses (61, 73). Furthermore, in secondary lymphoid organs
CD4+ T cells can modulate both B cell and CD8+ CTL responses
(74). Studies using murine models have shown that CD4+ T cells
can enhance the potency of CD8+ T responses (74). CD4+ T
cells have also been described in terms of their differentiation
into various T helper lineages marked by distinct transcription
factors and cytokine production (73, 75). The most studied of
these lineages are TH1, TH2, TH17, T follicular helper (TFH)
and CD4+FOXP3+ Treg (73). While the complex functions of
each subset in various tumor types remain poorly described and
require further investigation, it is generally accepted that Th1
cells promote effective anti-tumor immune responses via the
production of large amounts of IFNγ, promoting not only CD8+
CTL function but also recruiting NK cells and classically activated
M1 macrophages (73). Alternately, Treg are hypothesized to assist
tumor growth due to their capacity to inhibit effector T cells and
to mediate immunosuppression (10, 76).
As mentioned earlier, a majority of studies on the prognostic
value of TIL in melanoma have utilized TIL pattern scoring in
H&E tissue with very few reports examining TIL subsets in situ
using IHC (10, 12, 30). In aforementioned study using primary
cutaneous melanomas (Stage II), the authors demonstrated that
while the presence of GZMB+ TIL was associated with longer OS
and progression-free survival (PFS), the presence of CD4+ and
CD8+ TIL was associated only with improved PFS and not OS
(68). However, in the context of metastatic melanoma, there are
no conclusive studies demonstrating the prognostic significance
of CD4+ TIL assessment using histopathology (12, 30). A recent
report using multi-parameter flow cytometric profiling revealed
that proportions of naive CD45RA+CD4+ T cells in mLN
of stage III cutaneous melanoma patients, inversely correlated
with the frequencies of CD8+ T cells (69). Furthermore it was
observed that patients with markedly higher proportions of naive
CD45RA+CD4+ T cells in their tumors exhibited significantly
reduced PFS (69). Finally, the surface markers CD69 and PD-1
were also found to be expressed on CD4+ T cells in metastatic
tumors but the prognostic value of assessing these markers using
immunohistochemistry or in situ IF remains to be demonstrated
in melanoma (69).
Currently, only a limited number of studies have investigated
the prognostic potential of CD4+ TIL enumeration in melanoma
using IHC or IF (12, 30). Using TMAs constructed from
metastatic melanoma samples (from multiple anatomic sites)
and IHC to identify major TIL subsets, it was shown that
while higher densities of CD3+ and CD8+ TIL were positively
associated with OS, this was not the case for CD4+ TIL (31).
Nevertheless, a study which examined only melanoma metastases
within the SLN and enumerated intratumoral lymphocytes by
visual counting, higher counts of CD4+ TIL were significantly
correlated to increased OS and RFS (32). As SLN biopsy is
routinely performed to stage primary cutaneous melanoma,
assessment of various TIL subsets within metastatic SLN may
provide useful prognostic and biological insights on the roles
of these cells in cancer immunity (77). However, the studies
mentioned above complicate the interpretation of the roles of
CD4+ TIL in melanoma. First, the low number of studies
examining TIL subsets in melanoma and the diverse techniques
used to identify and enumerate labeled cells do not allow for
standardized comparisons between multiple reports (12, 30).
Second, it is not possible to characterize the diversity of CD4+
T helper lymphocytes by labeling only the surface antigen
CD4. While TH1 CD4+ TIL are considered to augment cancer
immunity, the roles of TH2 and TH17 are more nuanced and
their involvement in tumor development and progression are
not fully understood (73, 78). Knowledge of the mechanisms
through which T helper subsets influence tumor development
has been largely obtained from in vivo murine models where
both CD4+ TH1 and TH2 cells have been shown to eliminate
B16 melanomas (78). However, studying T helper subpopulations
is challenging in the context of immunopathology as they often
do not express unique surface markers and are defined by the
differential expression of key cytokines (73). As a result, a number
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of studies have performed gene expression profiling to assess TH1
or TH2 signature genes in human melanoma biopsies. A report
demonstrated that the expression of TH1 associated genes such
as TNFβ and IL-2 was significantly higher in primary melanoma
tumors which undergo spontaneous regression (a clinically
observed occurrence indicating the activation of host anti-tumor
immune responses) compared to non-regressing tumors (57).
Gene expression of the primary TH1 effector cytokine, IFNγ,
was also elevated in regressing primary tumors but these levels
did not reach significance (57). In another study, CD4+ T
cells from SLN of 13 cutaneous melanoma patients (positive
and negative LN were included) displayed a TH2 skewed gene
signature in association with increased production of VEGFA
(79). While the differentiation of T cells into various effector
subpopulations is still not fully understood, it is known that
specific transcription factors regulate the differentiation of CD4+
T cells into various T helper lineages such as TH1 (T-bet), TH2
(GATA-3) TH17 (RORγt) and Treg (FOXP3). Thus, in some
settings, IHC for T-bet+ cells in tumor tissue has been performed
as a readout for TH1 cells. In primary tumors of colorectal as
well as ovarian cancer, increased numbers of T-bet+ cells were
found to be associated with improved prognosis in patients
(80, 81). However, similar studies have not been reported in
the literature for melanoma (12, 30, 33). Furthermore, using
T-bet as a marker for TH1 cells in single or dual marker IHC
may lead to biologically invalid assumptions as shown by recent
work demonstrating that Treg can also express T-bet (82). In
a landmark paper, Levine et al. showed in murine models that
T-bet is stably expressed by Treg cells and the depletion of
T-bet+ Treg in mice resulted in pronounced TH1 autoimmune
responses (82). Thus, the latest studies have challenged the
accepted paradigms of T helper cell differentiation and as
such, assessing CD4+ TIL in cancer tissue will necessitate
the evaluation of a number of specific phenotypic markers
in addition to CD4+ to study the biological and prognostic
relevance of each subset. This is especially valid in view of the
observed diversity in Treg populations in cancer and the divergent
results from studies which have utilized FOXP3+ to examine
tumor-infiltrating Treg (10, 83).
FOXP3+ TIL (Treg)
Regulatory T cells i.e., Treg, are essential for maintaining self-
tolerance and as such, are crucial for the proper functioning
of a healthy immune system (76, 84). However, in the context
of cancer, Treg can limit anti-tumor immune responses thereby
contributing to an immunosuppressive TME (76). To date,
the best characterized population of regulatory T cells are
CD4+CD25+FOXP3+ Treg and in the literature, the term Treg
is primarily applied to that aforementioned subset (84). CD4+
regulatory T cell populations which lack FOXP3 expression
such as Tr1 (Type 1 regulatory) have also been described but
their specific functions are yet to be fully characterized (84).
Moreover, the expression of FOXP3 is not restricted to CD4+
Treg and has been reported in both normal and neoplastic
epithelial tissue as well as in other immune cells such as CD8+
T cells (76, 85). Similar to CD4+FOXP3+ Treg, CD8+FOXP3+
T cells with apparent immunosuppressive capacity have been
reported in human malignancies such as colorectal cancer and
ovarian cancer (76). Nonetheless, CD4+CD25+FOXP3+ T cells
remains the central focus of Treg-based research in cancer biology
due to their potent immunosuppressive functions and their
presence in a wide range of tumor types (76, 86). The recently
observed diversity within Treg populations and the mechanisms
through which Treg suppress immune responses have been
reviewed elsewhere (76, 86, 87). The major mechanisms of
Treg immunomodulatory functions can be divided into four
categories as follows: a) release of immunosuppressive cytokines
such as IL-10, IL-35 and TGFβ, b) direct cytotoxicity to
activated cells via granzymes and perforin, c) direct regulation
of APC function through surface expression of the checkpoint
molecule CTLA-4 and d) nutrient deprivation of effector cells
through high surface expression of the IL-2 receptor subunit
α (CD25) leading to reduced IL-2 levels for effector T cell
activation (87–89). Canonically, Treg were also purported to
induce metabolic disruption of activated immune cells through
the surface molecules CD39 and CD73 which converts ATP
to AMP (via CD39) and eventually to adenosine (via CD73)
leading to immunosuppressive signaling in effector T cells
and APC through the adenosine A2A receptor (A2AR) (86,
87). Nevertheless, a recent study suggests that in human
cancers, CD73 is expressed on only a limited proportion of
Treg and a higher proportion of conventional T cells, while
CD39 is the more commonly expressed ectonucleotidase on
intratumoral Treg (90). Blocking both the surface bound and
soluble form of CD39 and CD73 through antibodies was recently
shown to synergistically rescue human T cells from ATP-
mediated suppression, suggesting the utility of such an approach
for cancer immunotherapy (91). Due to the broad range of
immunoregulatory capacities of Treg, they play an important role
in promoting an immunosuppressive TME (87). Murine models
of cancer have shown that depleting Treg (using specific ablation
of Foxp3 or anti-CD25 antibodies) lead to enhanced anti-tumor
immune responses, demonstrating the biological significance
of these cells to tumor progression (86). Treg proportions are
increased in malignant tissue, while Treg make up 2–5% of all
CD4+ T cells in the peripheral blood of healthy individuals,
between 10 and 50% of CD4+ T cells in tumors are reported
to be Treg (87). An important distinction between Treg is
determined on the basis of their origin. Natural or thymic Treg
(tTreg) originate in the thymus and have key functions in the
maintenance of self-tolerance in healthy individuals, while in the
periphery, induced Treg (iTreg) can be generated as a result of
a number of stimuli (87). The transcription factor Helios and
the transmembrane protein neuropilin 1 have been proposed to
be markers for tTreg but recent research has shown that these
markers may not be exclusive to tTreg as Helios expression has
been seen in both tTreg and iTreg (76, 87).
In histopathology, FOXP3 remains the primary marker for
detection of Treg in fixed tumor tissues. FOXP3+ TIL are
associated with poor prognosis in most cancers including breast
cancer, lung cancer and pancreatic cancer, but in the case of
colorectal or gastric cancer, FOXP3+ TIL correlate to improved
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clinical outcomes (10). In cutaneous melanoma, a number of
reports have shown that FOXP3+ TIL are associated with a
negative prognosis, while others have reported no significant
association (10, 30). As discussed earlier for both CD4+ and
CD8+ TIL, the staining approach and the enumeration method
for FOXP3+ Treg varies between studies which may account for
the inconsistency between multiple reports. In a 2007 report,
studying two groups of melanoma patients who either exhibited
or did not exhibit local disease recurrence, it was shown that
the percentage of CD4+ T cells which were CD25+FOXP3+
(as determined by dual IHC) was significantly elevated in
the primary tumors of patients who had recurrent disease
(92). This study therefore demonstrates that the methodologies
used to detect, enumerate and compare FOXP3+ TIL are
vital to determine their association with clinical parameters.
In a subsequent study of primary tumor biopsies from over
90 melanoma patients, FOXP3 was detected via IHC and
enumerated visually both in the intratumoral and stromal regions
but failed to show a significant associations with patient survival
or any other clinical parameter such as tumor thickness or
ulceration (93). In a TMA consisting of metastatic melanoma
lesions (multiple anatomic sites) from over 140 patients, FOXP3+
cell density did not show a prognostic association with survival
(31). However, the functional and prognostic relevance of Treg
in a tumor may vary depending on whether it is a primary
tumor or a metastatic lesion. In the aforementioned report by
Kakavand et al. who examined metastatic SLN, a strong trend
was observed for a negative association between high counts
of FOXP3+ TIL and recurrence-free and overall survival (32).
As for other immune cell genes, qPCR for FOXP3 can also be
performed as a readout for Treg abundance and in a study of
metastatic SLN, patients with very high levels of FOXP3 gene
expression (>90th percentile) displayed significantly lower PFS
(94). While gene expression profiling is not routinely utilized in
histopathology to study the diversity of TIL subsets, the studies
discussed here show that gene expression profiling may provide
a useful immunophenotyping tool in the TME. In addition to
qPCR, mRNA fluorescent in situ hybridization (FISH) provides
a useful tool for immunophenotyping tumor tissue. For instance,
mRNA FISH was utilized to detect PD-L1 mRNA expression in
primary breast carcinomas and was shown to be associated with
longer RFS (95). In addition to CD25 and CTLA-4, Treg also
express a number of other key surface molecules such as ICOS,
OX40, GITR and TIGIT (86, 87). However, as these markers
are not exclusive to Treg, detection of FOXP3 in tumor tissue
is inferred to represent CD4+CD25+FOXP3+ Treg (12, 30).
Nonetheless, recently work has demonstrated that a population
of FOXP3+ non-Treg cells are also found in cancer (87). As such,
FOXP3+ populations in CD4+ T cells are currently classified into
three fractions based on their expression of CD45RA and FOXP3.
These include naive Treg (CD45RA+FOXP3loCD25loCD4+),
effector Treg (eTreg, CD45RA−FOXP3hiCD25hiCD4+) and non-
Treg (CD45RA−FOXP3loCD25loCD4+) (87). FOXP3+ non-
Treg are considered immunostimulatory and may account
for the reported association between increased FOXP3+ TIL
and improved prognosis reported for certain cancers such as
colorectal and gastric cancer (87). Therefore, FOXP3+ TIL
represent a heterogeneous population of cells and further
research is required to identify markers to clearly differentiate
immunosuppressive FOXP3+ Treg from FOXP3+ non-Treg, for
their use in histopathology and therefore allow immunologists
to better study classical immunosuppressive Treg in tumor
tissues. Furthermore, as for other TIL subsets, a standardization
of methodologies for IHC detection and enumeration of
Treg will allow for the pooling of results between multiple
studies in order to determine the biological roles of both
immunostimulatory and immunoregulatory lymphocytes in situ
not only in tumor tissues but also in autoimmune disease and
organ transplantation.
TUMOR-INFILTRATING B CELLS
Currently, the roles of B cells in tumor immunity are not fully
characterized and studies examining their prognostic potential
are limited (56, 96). Cancer patients are observed to produce
antibodies to a wide range of tumor antigens, in particular,
overexpressed antigens or neoantigens resulting from somatic
mutations (96, 97). Moreover, autoantibodies are also detectable
in a wide number of malignancies (96). While antibodies specific
to tumor cells can in theory, lead to their elimination through
complement activation, macrophage phagocytosis and NK cells,
at present there is not sufficient evidence to indicate whether
autoantibodies or tumor-specific antibodies can independently
control disease progression in cancer (96, 97). However, B
cells also display important effector functions apart from the
production of antibodies and experimental evidence has shown
that B cells can both restrain and promote anti-tumor immune
responses (96–98). Briefly, B cells can hinder tumor progression
by promoting cytotoxicity to tumor cells, producing tumor-
specific antibodies and as APC, particularly when DC function
may be impaired or where DC may be absent (96, 97). Conversely,
murine models have demonstrated a wide range of potentially
pro-tumorigenic activity of B cells. For instance, circulating
immune complexes resulting from B cell produced IgG induce
chronic inflammation and myeloid cell activation while B cell
secreted lymphotoxin can promote the growth of cancer cells
(97). Recently, a number of studies have also shown the important
role of B cell subsets with immunoregulatory function, i.e., Breg
(96, 99). Currently, hypothesized to be essential for maintaining
self-tolerance, numerous B cell subsets display Breg function
defined primarily by their production of IL-10 and in certain
subsets, IL-35 (99). An additional important subset of tumor
associated Breg were described in mice by Olkhanud et al. in 2011
(100). These CD25+CD19+B220+ cells termed tumor-evoked
Breg (tBreg) were observed in a murine breast cancer model (4T1)
and were found to produce high levels of TGFβ (100). In a TGFβ-
dependent manner, these cells were further shown to induce Treg
from conventional CD4+ T cells and were observed to be vital
in promoting lung metastasis in this model (100). The authors
also found evidence for the existence of such a population in
humans as CD19+ B cells from healthy donor blood, upregulated
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CD25 and suppressed T cell proliferation following treatment
with ovarian and colon cancer cell conditioned medium (100).
The capacity to induce Treg and promote metastasis suggests
an essential role for this subset in disease progression. Due
to their diversity of function and phenotype, Breg are now
recognized as a crucial immunoregulatory population in human
cancers (12, 56).
A recently reported systematic review of 69 studies in 19
different types of cancers showed that most studies identified
a positive or neutral association of B cells with survival, with
fewer than 10% reporting a negative association (56). The most
commonly used IHC marker for B-TIL is CD20, which detects
both naive and memory B cells, but not differentiated plasma
cells (PC), which are identified in most IHC studies as CD138
(syndecan-1) positive (12, 56). Other IHC markers utilized for
PC include the immunoglobulin kappa constant (IGKC) as well
as the ER-associated protein p63 (56). The transcription factor
Pax5 is also used to establish the B cell lineage of lymphoid
cancers (101). However, according to a recent meta-analysis,
its use as an IHC marker for B-TIL in tumors has not been
investigated (56). As previously described for other TIL subsets,
in situ studies have revealed tumor-infiltrating PC and CD20+
B-TIL to be associated with both positive and negative prognostic
outcomes (56). Relatively few studies have examined B-TIL in
cutaneous melanoma with only two reports demonstrating a
positive, one showing no effect and one revealing a negative
prognostic association of CD20+ B cells (56). In 2011, Ladányi
et al. showed that increased numbers of both intratumoral and
peritumoral CD20+ B-TIL in cutaneous primary melanomas
were associated with increased patient survival (102). In this
report, activated T cells were also enumerated using the markers
CD25 and OX40 (CD134). By combining B cell counts with
activated T cell counts, patients were classified as high or low
for CD20 and CD25 or OX40. It was observed that patients with
high B cell and high activated T cells demonstrated the highest
5-year survival rates in the cohort while patients from the low B
cells/low activated T cell subgroup displayed the poorest survival
of all subgroups (102). In a more recent report in 2016, high
numbers of CD20+ B cells in primary cutaneous melanomas
with a Breslow thickness >1 mm were associated with improved
survival (103). In addition, analysis of gene expression data from
TCGA for over 300 cutaneous melanomas (primary tumors and
metastatic tissues) showed CD20/CD19-high patients to exhibit
significantly improved OS (103). In both of the aforementioned
reports, the authors also found that primary tumors from patients
with metastases displayed lower numbers of B cells compared
to tumors from patients without metastases or in the case of
the earlier report, patients without visceral metastases (102, 103).
Therefore, these studies suggest that CD20+ B-TIL might serve
an important role in promoting tumor immunity and limiting
disease progression in melanoma. Further evidence for this
notion is available from a study in metastatic melanoma lesions
(multiple anatomic sites), where high numbers of both CD20+ B
cells and CD138+ PC were found to be associated with improved
survival (31). In the same report, they demonstrated that higher
numbers of CD8+ TIL but not CD4+ TIL were associated with
increased survival in metastatic melanomas (31). Thus, further
studies are required to elucidate potential mechanisms through
which B cells may promote CD8+ TIL responses. While it is
known that B cells can produce immunostimulatory cytokines
and act as APC, their precise effects on T cells in the TME
remain poorly characterized (56). In contrast to the reports
described above, a negative prognostic association has also
been observed for B-TIL and PC in melanoma. In a study of
91 primary cutaneous melanomas where both CD3+ TIL and
CD20+ B-TIL were enumerated, the latter were found to be
associated with poor survival in cases where they represented
15% or more of all TIL (104). As this study utilizes a cut-off
of CD20+ TIL as a proportion of CD3+ and CD20+ TIL, a
comparison of their results to other studies which determined
an association between survival and absolute numbers of B-TIL
is particularly challenging. Furthermore, these findings are not
in corroboration with studies in larger cohorts discussed above
or with mechanistic studies in murine models. Depletion of
B cells with an anti-CD20 antibody in B16 melanoma bearing
mice resulted in increased tumor volume, metastatic capacity
and impaired T cell immunity (105). As a whole, it can be
inferred that while certain B cell subsets such as Breg may be
immunosuppressive (99), improved survival of patients with high
CD20 gene expression and with high numbers of CD20+ B-TIL
in the majority of patient cohorts reported thus far, strongly
supports an anti-tumor role for conventional B cells in cutaneous
melanoma. In a study of primary cutaneous melanomas, it was
observed that cases with high levels of PC (CD138+) displayed
worse OS than those without any PC (106). Notably, however,
cases with low numbers of scattered PC displayed better OS
compared to cases with high PC scores (106). These observations
suggest that both the functional diversity as well as the spatial
localization of B cells and PC are important considerations when
determining their prognostic and biological significance in the
TME. Notably, the formation of ectopic lymphoid aggregates
termed tertiary lymphoid structures (TLS) has been noted in
many types of tumors and these TLS are zones of B cells, T
cells and DC akin to secondary lymphoid organs (SLO) (107).
As such, the prognostic and mechanistic significance of the
localization of B-TIL and other leukocytes within TLS is a
vital avenue of investigation in tumor immunology and cancer
histopathology (107–109).
TERTIARY LYMPHOID STRUCTURES
TLS are transient ectopic lymphoid tissues which develop in the
context of chronic inflammatory responses such as in chronic
viral infections, autoimmune diseases, allograft rejection and
cancer (108, 110). TLS in the tumor can vary in complexity from
lymphocyte clusters to highly organized, spatially segregated
structures bearing a strong resemblance to SLO, in particular,
LN (107, 108). Thus, with the exception that highly organized
TLS are not surrounded by fibrous capsules akin to LN, they
are nevertheless recognized histologically by many of the same
features as LN (107). TLS are also observed to contain high
endothelial venules (HEV), distinct T cell zones with mature
DC and B cell follicles with a germinal center, and evidence
Frontiers in Immunology | www.frontiersin.org 9 September 2020 | Volume 11 | Article 2105
fimmu-11-02105 September 8, 2020 Time: 18:21 # 10
Maibach et al. Emerging Advances in TIL Profiling
of antibody class-switching (107, 108). The precise mechanisms
through which TLS are induced in tumors are not fully described
and the research pertaining to TLS neogenesis has been recently
reviewed (107, 108). Studies demonstrate that TLS generation
in tumors involves many of the same molecular signals as the
formation of LN, such as lymphotoxin, CCL21 and CXCL13
(108, 109). However, instead of lymphoid tissue inducer (LTi)
cells which modulate LN formation, multiple cell types have
been shown to be involved in the generation of TLS including
DC, naive B cells, macrophages, TH17 and NKT cells (108).
While significant further research is required to uncover the
mechanisms through which TLS form and to determine their
exact roles in situ, the induction of TLS as a therapeutic approach
has been examined in murine models (107, 109). These strategies
have varied from use of the LTβR ligand LIGHT (TNFSF14)
to adoptive transfer of DC expressing CCL21, and have shown
efficacy in a number of diverse tumor models (109). Nevertheless,
the therapeutic use of TLS induction necessitates a more detailed
understanding of their roles in tumor immunity.
Histologically, TLS are found in a proportion of cancers of
various types such as NSCLC, melanoma and colorectal cancer
(107, 109). They are usually located in the invasive margin or in
the stroma rather than the tumor core, and HEV are detected in
close proximity to TLS (109). Using H&E, mature TLS can be
identified either as well differentiated lymphoid follicles which
include structures resembling germinal centers (109). TLS can
be identified by IHC using the marker DC-lysosome-associated
membrane glycoprotein (DC-LAMP) for mature DC, or CD20+
B cell follicles next to a CD3+ T cell zone (109). In addition to
these markers, TLS also contain CD68+ macrophages, CD138+
PC and HEV expressing peripheral node addressin (PNAd) and
vascular addressin (MECA-79) (109). Finally, a number of gene
expression profiles, comprised of genes for key chemokines such
as CCL19, CCL21 and CXCL13, or a combined TH1 and B cell
signature, have been utilized to determine the presence of TLS
in tumor tissues (111, 112). An increasing body of evidence
indicates that TLS are potent modulators of the immune response
in tumors where they are found (109, 113). Generally, tumors
with high TLS presence are also marked by features of CD8+
T cell activation, a TH1 tilted CD4+ repertoire and mature
DC (108, 109). Furthermore, TLS are also purported to be
involved in the generation of tumor-specific antibody responses
and support antigen presentation and activation of T cells via
B-TIL (109). This crucial interaction between B-TIL and T cells is
further supported by the previously discussed systematic review,
where the prognostic effect of CD3+ and/or CD8+ TIL was
stronger when B cells (CD20+ B-TIL or PC) were present (56).
Given these observations, it is unsurprising that increased TLS
density or specific TLS features such as HEV, has been shown
to be associated with improved survival in a range of different
tumor types including lung cancer, colorectal cancer, pancreatic
cancer and melanoma (107, 109). Nevertheless, there are a few
studies which have shown that TLS may also be negatively
associated with patient outcomes. In patients with hepatocellular
carcinomas (HCC), a histologically validated TLS gene signature
was found to be associated with poor patient survival and
subsequent investigations in an HCC murine model revealed that
TLS served as a niche for progenitor HCC tumor cells (114).
These findings are in accordance with additional observations in
the literature that TLS in a breast cancer cohort were associated
with a higher tumor grade, and with murine studies showing
that Treg can also be found in TLS and control anti-tumor
immune responses (115, 116). Thus, the mechanisms underlying
whether TLS adopt immunosuppressive/pro-tumorigenic or
immunogenic roles in a particular TME are not elucidated and
require further study.
In cutaneous melanoma, only a limited number of studies
have examined the associations of TLS with patient survival
and TLS are deemed to be a favorable prognostic factor in
this tumor (107, 109). In a 2007 report examining DC and
T cell numbers in primary cutaneous melanomas, the authors
reported that while CD1a+ DC were detected in the intratumoral
and stromal regions, DC-LAMP+ (mature) DC were located in
peritumoral regions in association with lymphocyte aggregates
(117). An increased density of both DC correlated positively
with higher numbers of activated (CD25+ or OX-40+) T cells
and DC-LAMP+ were significantly associated with longer patient
survival (117). In a subsequent 2011 study by the same group they
showed an association of CD20+ B-TIL density with improved
survival in patients with primary cutaneous melanomas (102). In
the same report, the authors noted the presence of follicle-like
B cell aggregates in 26% of their cohort but did not observe any
association of these structures with survival (102). In 2012, it was
shown that fully formed TLS could be detected in a proportion
(24%) of skin metastases of patients with cutaneous melanoma,
with follicular dendritic cells, B cell follicles, DC-LAMP+ DC
and PNAd+ HEV, while primary melanomas contained HEV
but not fully developed TLS (118). However, the biological
roles of these structures in the metastatic process or disease
progression remain to be deciphered (118). In another report
from 2012, PNAd+ (detected by the MECA-79 antibody) HEV
were found to be present in nearly two-thirds of all 225 primary
melanoma tumors examined (119). Furthermore, HEV were
observed in the vicinity of DC-LAMP+ mature DC and HEV
density was strongly correlated to that of CD8+ and CD20+
TIL (119). Ultimately, the authors showed that high levels of
HEV were correlated with low Clark invasion levels and lower
Breslow thickness indicating that HEV play an important role
in promoting tumor immunity in melanoma (119). Collectively,
these findings support a role for TLS in mediating anti-tumor
immune response.
These findings are also corroborated by transcriptomic
profiling. As discussed earlier, the presence of TLS may also
be determined using gene expression analysis (109). High
expression of a 12-chemokine gene signature previously validated
in colorectal cancer, was able to detect TLS in non-locoregional
melanoma metastases (120). By comparing the tumors with the
highest and lowest scores for this 12-gene signature, it was
shown that tumors with low scores exhibited minimal or no
lymphocyte infiltration, whereas high scoring samples displayed
a notable lymphocyte infiltration with the presence of TLS both
intratumorally as well as at the tumor-stroma interface (120).
These TLS contained discernable lymphoid follicles with CD20+
B cells, CD86+ DC, and both CD4+ and CD8+ T cells but
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very few FOXP3+ Treg (120). Finally, the authors showed that
the 12-gene expression score was also correlated to the survival
of patients with melanoma metastases (120). These results are
of particular interest, as the 12-chemokine score can be used
to query microarray or RNA-seq data from tumors sample
for which archival whole tissue is also available. Such tissue
might then be analyzed using IHC and IF techniques to further
dissect the architecture and the prognostic/predictive relevance
of TLS. Nevertheless, in a recently published systematic review
of TLS in cancer, the authors conducted an in-depth analysis
of tumor RNA-seq profiles from TCGA for the presence of TLS
genes and various cellular subtypes using immune deconvolution
algorithms (109). It was shown that while the 12-chemokine gene
signature was found in tumors with higher abundances of T
cells, B cells and DC, there was significant heterogeneity among
tumor types in their expression of the aforementioned signature
(109). While cutaneous melanoma displayed the signature at high
levels, uveal melanomas revealed a very low level of expression,
which was also the case for tumors from other immune-privileged
anatomical locations (e.g., glioblastoma) (109). As such, further
research is required to determine the molecular events which
lead to TLS neogenesis in each tumor type. Furthermore, the
precise roles of various components of TLS in modulating
tumor progression remain largely unknown, in particular, that
of antibody-producing plasma cells (113). Finally, the prognostic
roles of TLS have only been reported for a limited number of
cohorts in various tumor types, and a larger, collective tissue
repository is required in order to perform more meaningful
histopathological analyses of TLS in melanoma as well as in
other tumor types.
TIL AS PREDICTIVE BIOMARKERS FOR
ICB RESPONSE
Mechanism of Action of ICB Drugs
The immune composition of the tumor reflects the continuous
interplay between the host immune response and the evasive
mechanisms utilized by the cancer cells to ensure their survival
(121, 122). Therefore, elevated numbers or proportions of specific
tumor-infiltrating immune cells have been observed to show
positive or negative prognostic associations with survival in
multiple tumor types (10, 12). However, TIL profiling has
also demonstrated predictive value for a subset of cancer
patients treated with chemotherapy and radiotherapy (123–
125). Furthermore, as mentioned above, it is established that
cytotoxic chemotherapies and radiation treatment can enhance
the immunogenicity of a tumor and shape the responses of
intratumoral immune cells, albeit the fact that many of the
mechanisms involved are not well described (126). Nevertheless,
given the wide range of cancer therapies currently in clinical
trials, including immune modulating agents and combination
treatments, a vast amount of future work is required to accurately
dissect the predictive value of various TIL subsets in response to
these therapies. Tumor immunotherapies have currently emerged
as a critical avenue of both preclinical and clinical research in
oncology. The major types of tumor immunotherapies, their
clinical efficacies and future therapeutic targets including novel
checkpoint molecules (e.g., LAG-3, VISTA) have been reviewed
expertly elsewhere (3, 4, 127). However, given that ICB with
anti-CTLA-4 and anti-PD-1 antibodies functions by promoting
T cell activation and the fact that it is currently utilized for the
treatment of metastatic melanoma, an investigation of whether
TIL subsets can serve as predictive markers for these treatments
is of significant clinical value (128). Both CTLA-4 and PD-1
surface molecules, like the co-stimulatory molecule CD28 are
members of the immunoglobulin superfamily but are bound
by distinct ligands and have unique mechanisms of action
(129). Thus, a brief description of their function is warranted.
The expression of CTLA-4 is enhanced immediately following
T cell activation (i.e., TCR stimulation) and by binding to
the co-stimulatory molecules CD80 and CD86 with a higher
affinity than CD28, CTLA-4 serves to limit T cell activation
(129, 130). Given that APC provide co-stimulatory signaling
to T cells via the interactions of CD80 and CD86 with CD28,
CTLA-4 putatively functions in secondary lymphoid organs
and is key for maintaining immune tolerance (130). Similarly,
the PD-1 pathway also attenuates T cell activation and is an
important mechanism in the prevention of autoimmunity in
peripheral tissues (130). PD-1 is expressed on activated T cells,
B cells and even NK cells (129). The primary ligand for PD-
1, PD-L1 is expressed by both immune cells and non-immune
cells while PD-L2 is putatively only expressed by APC in
normal tissues (129). The expression of PD-L1 and to a lesser
extent, PD-L2 is induced by pro-inflammatory cytokines such
as IFNγ (130). Binding of PD-L1 or PD-L2 is purported to
inhibit T cell activation via the tyrosine phosphatase SHP2,
although recent studies have shown that SHP2 is dispensable for
establishing T cell exhaustion in vivo suggesting the existence
of multiple redundant signaling mechanisms downstream of
PD-1 (130). While the molecular functions of CTLA-4 and
PD-1 have been described, an increasing body of literature
has shown that checkpoint blocking antibodies have distinct
and unique functions on the immune system in vivo (129–
131). However, in the clinic, anti-PD-1 antibodies (nivolumab
& pembrolizumab) result in significantly higher ORR and
lower toxicity profiles compared to anti-CTLA-4 antibodies
(ipilimumab) (6, 132). It is pertinent to note that due to
the very recent testing and implementation of these drugs,
there is variability in the reported ORR for each age. The
objective radiographic response rate was shown to be 15%
for ipilimumab in patients with metastatic melanoma (6).
Furthermore melanoma patients treated the anti-PD1 agents,
nivolumab and pembrolizumab, demonstrate a response rate
of between 35 and 40% while combination nivolumab and
ipilimumab therapy in melanoma results in responses rates of
approximately 60% (6). While ICB displays clinical efficacy in a
number of tumor types including melanoma, only a fraction of
patients display durable responses and certain forms of cancer,
such as pancreatic ductal adenocarcinoma (PDAC), remain
largely refractory to currently approved checkpoint inhibitors
(6, 133). Thus, there is a significant need to identify tumor-
specific features to identify potential biomarkers for successful
response to ICB.
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Predictive Biomarkers for ICB Response
Studies have shown that a wide range of tumor and host-
specific biological factors are associated with responses to
checkpoint inhibitor therapies. As reviewed recently, these
features include but are not limited to, tumor-specific genetic
features (tumor mutational burden or particular transcriptional
profiles), intratumoral expression of PD-L1, host-specific features
such as gut microbiota and finally, the immune composition of
the TME as well as the peripheral blood (134, 135). A number
of reports have shown for instance, that elevated neutrophil
to lymphocyte ratios in peripheral blood are associated with
decreased survival in a number of cancer types treated with anti-
CTLA-4 and anti-PD-1 ICB (135). A number of other features
assessed in peripheral blood such as T cell clonality, monocytes,
MDSC and Treg cells are purported to be associated with response
to ICB but require further investigation and validation (135).
However, it is the immunological composition of the TME which
remains a key focus of current research on the predictive potential
of immune cells for ICB. As previously mentioned, numerous
studies have investigated the roles of myeloid cells in modulating
both the immune response to tumors as well as response to tumor
therapies (135, 136). Thus, in keeping with the scope of this work,
this section will specifically discuss the association of TIL with
responses to anti-CTLA-4 and anti-PD-1 checkpoint drugs.
Due to the expression of PD-L1 by both tumor and immune
cells, it has been investigated as a potential biomarker for
determining response to anti-PD-1 ICB (134, 135). While the
positive correlations of PD-L1 expression to patient outcomes
have been reported in a number of studies, there is currently
insufficient evidence to define PD-L1 as an independent
biomarker for ICB response (134, 135, 137). It is important
to note that IHC-based detection of PD-L1 has been approved
as a biomarker for selecting pembrolizumab as a treatment
in NSCLC patients (135). However, PD-L1 both on immune
cells and tumor cells can be highly dynamic both in its spatial
and temporal expression (135). As such, multiple reports have
shown no association between PD-L1 status and ICB response
while other reports have shown that patients with no PD-
L1 expression display durable clinical responses to ICB (135).
Therefore, collectively from the literature, it is evident that PD-
L1 is not a comprehensive biomarker for response to ICB. This
is particularly important given observations that even when PD-
L1 is expressed, a pre-existing lymphocyte infiltrate is required
for induction of anti-tumor immune responses with checkpoint
inhibitors (134, 137).
To date, only a limited number of scientific reports have
investigated TIL profiling in cutaneous melanoma and its
potential association with response to ICB treatment in human
patients (134, 138). In a study in 2011, 82 patients with
unresectable stage III/IV melanomas treated with ipilimumab
showed, that at baseline, only positive immunostaining for
the markers IDO and FOXP3 in resected tumor biopsies,
could significantly distinguish patients who obtained clinical
benefit from those who did not (139). Indole-2,3-dioxygenase
1 (commonly referred to as IDO or IDO1) is a key enzyme
in tryptophan catabolism and in tumors, high IDO1 levels
derived from tumor cells and tolerogenic myeloid cells leads
to the inhibition of effector T cells and NK cells (140). While
baseline TIL scores in H&E stained biopsies were not elevated in
patients who displayed clinical responses compared to those who
did not, a majority of responding patients exhibited significant
increases in TIL scores following treatment (139). In a more
recent study which examined surgical biopsies (lymph nodes and
subcutaneous/cutaneous metastases) from melanoma patients
prior to treatment with ipilimumab, serial IHC for 11 leukocyte
markers was performed and cell were visually enumerated to
determine their association with response to therapy (141).
In LN metastatic lesions, densities of CD4+, CD8+, FOXP3+,
CD134+ and CD20+ lymphocytes as well as NKp46+ NK cells
were found to be significantly higher in responders compared
to non-responders (141). In separately evaluated subcutaneous
and cutaneous metastatic lesions, responders displayed only
higher densities of CD68+ and CD16+ leukocytes (141). These
results suggest that the surgical site of the biopsy warrants
further investigation when determining the predictive utility
of TIL profiling. Furthermore, when all metastatic lesions
were evaluated together, NKp46+, CD68+ and FOXP3+ cells
were found to be the most statistically significantly different
populations between responders and non-responders, in part
corroborating the findings of Hamid et al. above (139, 141). Given
that FOXP3 and IDO are markers for an immunosuppressive
TME, their association with response to ICB treatment might be
counter-intuitive (142). However, as demonstrated in a report by
Spranger et al., T cell inflamed tumors do exhibit high levels of
IDO, PD-L1 and FOXP3+ Treg and murine studies suggest that
these immunosuppressive mechanisms do not precede but are
instead induced following the infiltration of CD8+ T cells into
the tumor (143). Therefore, depending on the specific TME of
a metastatic lesion, or a primary tumor as well as the timing of
the biopsy, immunoregulatory cell markers such as FOXP3 might
predict successful ICB response.
As mentioned previously, ICB with anti-PD-1 antibodies
results in higher response rates than with ipilimumab (7).
However, as is the case for ipilimumab, there is a crucial need
for determining predictive biomarkers for anti-PD-1 drugs. In
2014, Tumeh et al. studied pre-treatment and post-treatment
biopsies of metastatic melanomas (multiple anatomic sites) in a
cohort of 46 patients treated with pembrolizumab (144). Using
logistic regression, the authors were able to show that the density
of CD8+ T cells at the invasive margin was the most optimal
predictive marker for response to pembrolizumab (144). Other
statistically significant predictors were CD8+ T cell density in
the tumor, and the densities PD-1+ as well as PD-L1+ cells at
the invasive margin and in the tumor (144). However, CD4+ T
cell densities at baseline in the tumor or at the invasive margin
were not shown to be predictive of response to pembrolizumab.
Similar to the patients who responded to ipilimumab, most
patients who responded to pembrolizumab also exhibited an
increase in CD8+ TIL from baseline (144). While further
studies are needed, it is evident that TIL have the potential to
serve as effective biomarkers for tumor immunotherapy drugs.
As discussed above for TIL profiling in prognostic studies in
melanoma, IHC is limited in the number of markers which can
be assessed simultaneously. A number of the findings made using
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IHC in situ are corroborated by results from multiparametric flow
cytometric analyses of immune biomarkers for response to ICB.
In a cohort of metastatic melanoma samples from patients treated
with pembrolizumab or nivolumab, PFS and response to ICB
were positively correlated with increased proportions of CD8+
T cells in tumor biopsies marked by high surface expression
of CTLA-4 and PD-1 (145). The frequencies of CTLA-4hiPD-
1hi CD8+ T cells were shown to be independent of anatomic
site of the biopsy or previous therapy, and treatment with anti-
PD-1 antibodies resulted in an increase in the frequency of
intratumoral CD8+ T cells with a simultaneous decrease in
intratumoral CD4+ T cells (145). Furthermore, Treg (defined
as CD4+FOXP3hiCTLA-4hi) were not significantly associated
with clinical responses and treatment with anti-PD-1 antibodies
resulted in increased frequencies of CD8+ T cells (145). These
findings are in accordance with the report by Tumeh et al. which
showed that baseline numbers of CD8+ TIL and intratumoral
PD-1+ cells were associated with clinical response to anti-PD-
1 therapy (144). Taken together, these studies demonstrate that
while CD8+ TIL density is a key biomarker for response to ICB,
assessing surface markers such as CTLA-4 and PD-1 or functional
molecules such as Granzyme B might identify subsets of CD8+
TIL with improved potential for predicting response to ICB.
Due to the heterogeneity between patients and tumor
types, multi-parameter immunophenotyping techniques such
as flow cytometry are of limited value and next-generation
high-throughput technologies might be required identify novel
immune biomarkers for ICB response. In a recent report,
scRNAseq of metastastic lesions led to the identification of
the transcription factor TCF7 as a marker for a subset of
CD8+ T cells which are enriched in tumors of patients who
respond to checkpoint therapy (anti-CTLA-4, anti-PD-1 or
dual treatment) (146). In contrast, non-responding lesions
displayed an enrichment of a CD8+ T cell subset expressing
multiple genes liked to T cell exhaustion such as LAG3
and TIM3 (146). Subsequent immunofluorescent labeling of
tissue sections from responding versus non-responding tumors
with CD8 and TCF7 demonstrated that increased numbers
of TCF7+CD8+ T cells were present in responders whereas
increased TCF7−CD8+ T cells were present in non-responders
(146). This study demonstrated the utility of high-throughput
single-cell profiling approaches for identifying novel markers
for clinically meaningful TIL subsets which can be readily
applied to routine histopathology. However, the clinical validity
of TCF7+CD8+ T cells as predictive biomarkers for ICB warrant
confirmation in larger cohorts. Finally, studies have shown that
checkpoint inhibitors can lead to the expansion of distinct TIL
subsets, with anti-CTLA-4 and anti-PD-1 antibodies displaying
differences effects on various lymphocyte subsets thereby leading
to treatment-dependent shaping of the immune repertoire in
tumors (147, 148). While these studies permit us to understand
the intricate mechanisms through which checkpoint inhibitors
mediate their therapeutic effects, selecting treatments and
outcome prediction requires biomarkers which can be assessed in
pre-treatment biopsies. As discussed in this section, collectively
the literature suggests that TIL subsets such as CD8+ and
FOXP3+ T cells are potentially useful biomarkers for predicting
response to ICB. However, this requires validation in larger and
better stratified cohorts, thereby permitting the identification of
TIL subsets capable of predicting response to anti-PD-1 and
anti-CTLA-4, respectively. Finally, while a single TIL population
might not be predictive of response to therapy by itself, a
combination of immune-specific and tumor-specific proteins
might provide a more comprehensive marker panel for predicting
checkpoint response. The TME is highly dynamic representing
a continuous interplay of tumor cell and stromal cell derived
factors with tumor-infiltrating immune cells and leukocyte
derived molecules (149). The underlying driver mutations in
cancers are key modulators for the expression of molecules which
influence immune cell function (149). BRAFV600E is a key driver
mutation in melanoma, and is known to promote the expression
of IL-10, IL-6 and VEGF, factors which are purported to assist
in the induction of an immunoevasive TME (149). Therefore,
combined assessment of both TIL-specific and tumor-derived
molecules in surgical biopsies might uncover biomarkers which
can predict patient outcomes or response to therapy with high
accuracy. Finally, it is relevant to note that while scRNAseq
and mass cytometry can unveil the diversity of the immune
contexture in tumors in exquisite detail, these technologies offer
no information on spatial configuration. However, a number of
next generation, in situ profiling methods have recently been
described which might offer improved capacity to detect immune
cell subsets with prognostic and predictive potential for cancer.
NEXT GENERATION APPROACHES FOR
TIL PROFILING
An overview of the published literature on TIL profiling
shows that measuring TIL densities and phenotypes offers
important mechanistic insight into tumor immunology (12, 23).
Furthermore, TIL profiling has shown to offer prognostic value
for patient outcomes as well as provide predictive information
about successful response to ICB (12, 135, 138). However,
the literature also reveals that there is a lack of consensus
on methods for the identification, enumeration and scoring
of TIL subsets, even in the context of well-studied tumor
types such as melanoma (12, 30). Furthermore, in order to
discover novel spatial relationships and phenotypic details,
highly multiplexed approaches are required. Thus, this section
will discuss two critical aspects of next-generation profiling
approaches in cancer and their use in cutaneous melanoma.
First, we will review a novel scoring algorithm for tumor
infiltrating immune cells labeled “Immunoscore,” which has
already been shown to have excellent prognostic potential and
reproducibility in colorectal cancer (150, 151). Second, we will
examine novel in situ immunophenotyping technologies which
harbor significant promise for unveiling the complexity of the
TME, particularly the immune contexture.
Immunoscore
Currently, IHC-based detection of various TIL-specific markers
(e.g., CD3, CD8, FOXP3) on serial sections of tumor tissue is one
of the primary approaches for profiling the lymphocyte infiltrates
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in the TME (10, 12). As such, assessing lymphocyte densities as
ratios such as CD8/FOXP3 or CD4/CD8 has been investigated
and has shown to have prognostic potential in certain
tumor types, but warrants further validation and systematic
investigation (152, 153). However, a novel scoring algorithm
for intratumoral lymphocytes termed the “Immunoscore” has
been established as a potent prognostic tool in colorectal cancer
(150, 154). Immunoscore ranges on a scale from I0-I4 and is
based on digitally quantified densities of IHC-labeled CD3+
and CD8+ T cells, both in the tumor center (CT) and at
the invasive margin (IM) (150, 154). Using a dedicated image
analysis software (Immunoscore R© Analyzer, HalioDx, France),
an operator defines specific regions (tumor, healthy tissue,
necrosis etc.) and validates the CD3 and CD8 stains (154). An
IM extending 360 µm into the healthy tissue and 360 µm
into the tumor is automatically determined by the software
(154). In stage I, II and III colorectal cancer, Immunoscore
performed better as a prognostic factor for DFS, OS and
DSS compared to the AJCC/IUCC (American Joint Committee
on Cancer, International Union for Cancer Control) TNM
staging system which examines the primary tumor (T), LN (N)
involvement and metastases (M) (154). In a recent international,
multi-center study from over 13 countries, colorectal cancer
tissue samples from over 2,500 patients were analyzed by
Immunoscore demonstrating high reproducibility and reliability
of the assay across different centers (151). Furthermore patients
with a high Immunoscore had a significantly reduced risk of
disease recurrence at 5 years compared to patients with a
low Immunoscore (151). Given that the Immunoscore assay
qualifies most of the characteristics of an ideal biomarker
(rapid, robust, reproducible, quantitative etc.), it has received
regulatory approval for clinical use in colon cancer as an in vitro
diagnostic and it has been advocated to include an immune
component to TNM staging (TNM-I) in order to provide a
more comprehensive prognostic assessment (154). Given the
utility of Immunoscore in colon cancer, there have been efforts
to translate it to additional tumor types such as melanoma,
breast cancer and NSCLC (155). As such, the clinical validation
of Immunoscore as a prognostic and predictive biomarker
(for ICB) in these other tumor types are still underway while
additional TIL markers such as CD20 and FOXP3 have also been
included in evaluating the Immunoscore in melanoma (155).
An additional aspect of adapting Immunoscore for prognostic
use in advanced cancers, including melanoma is assessing its
utility in biopsies from metastatic lesions where the IM is
rarely available (154). However, Immunoscore has been adapted
and tested for biopsies without IM and was shown to be
prognostic as well in colorectal cancer, although this warrants
further investigation (154). Ultimately, it is crucial to note
that while CD8+ T cells are an essential component of tumor
immunity, a number of additional immune cell types have
shown prognostic associations in cancer such as FOXP3+ Treg,
CD20+ B-TIL as well as myeloid cells such as M1 and M2
macrophages (10). Taken together, as Immunoscore has yet
to be further studied for melanoma and a number of other
tumor types, incorporation of additional immune markers into
a more comprehensive Immunoscore might possess significantly
enhanced prognostic potential for clinical outcomes or predictive
utility for ICB.
State-of-the-Art TIL Profiling
As novel imaging and molecular technologies emerge, the
capacity to assess multiple markers simultaneously offers
significant promise for discovering actionable and clinically
relevant immune markers in cancer. Studies have shown that it
is now possible to assess multiple RNA molecules at a single-
cell resolution using single-molecule FISH (fluorescent in situ
hybridization), and a recent report has demonstrated an iterative
immunofluorescence (4i) based approach for multiplexed
profiling of up to 40 proteins simultaneously (156, 157). However,
these technologies are in their early phase of development and
their application to tumor tissue immunophenotyping in situ has
not been tested. In recent years, a series of detection methods
involving cyclic immunofluorescence, nucleotide tagging or
metal ion tagging as well as a number of novel image
analysis softwares have been developed for simultaneous
detection of multiple protein markers (as reviewed recently)
(158). NanoString Technologies has also recently revealed the
GeoMxTM digital spatial profiling (DSP) technique, where mRNA
or antibody probes are bound to photocleavable oligonucleotides
(159). Using digital micromirror devices, ultraviolet light is
guided to specified regions of interest in tissue labeled with
fluorescent markers to visualize tumor (e.g., PanCK) and immune
(e.g., CD45) regions (159). However, although this technique
permits the spatially resolved simultaneous detection of large
numbers of RNA or protein markers in FFPE tissue, it does not
permit multiplex visualization of multiple markers on single cells
(159). Given that the focus of this section is about technologies
which can provide detailed immunophenotyping of TIL in situ,
we will briefly discuss the nature of two major techniques which
are currently in development for the simultaneous visualization
of multiple protein markers in FFPE tissue (158).
Due to the fact that immunofluorescent labeling techniques
are still used extensively in clinical cancer research, it is
pertinent to briefly describe the methodologies currently in
use for multiplexing using immunofluorescence. Currently, one
technique for multiplexed immunofluorescence (mIF) in tumor
tissue is based on sequential staining using tyramide coupled to a
fluorophore, such as the OpalTM system by PerkinElmer (160).
Briefly, a single primary antibody is labeled using the OpalTM
HRP polymer and a single fluorophore followed by stripping
of the bound antibodies using a special microwave (160). Using
this approach, it is possible to multiplex up to 9 markers on
the same cell, thereby yielding far more important on the TME
compared to single or dual color IHC (160). Another recently
described approach which demonstrates significant potential for
multiparameter immunophenotyping of FFPE tissue tissue-based
cyclic immunofluorescence (t-CyCIF), uses sequential rounds
of immunofluorescence imaging in 4 channels to assess up to
60 markers (161). This process involves labeling and imaging
with 3 antigens per cycle with a DNA marker to locate and
register images across all cycles. This is followed by bleaching the
fluorophores in the presence of white light before another cycle
of immunolabeling. Finally all image tiles are stitched together
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and analyzed (161). The t-CyCIF approach has significant
value for TIL profiling in human tumor biopsies. The repeated
labeling and bleaching steps are labor-intensive and therefore the
reproducibility of this approach across various research groups
has not yet performed comprehensively. Nonetheless, t-CyCIF
is a cutting-edge approach for multiplexed immunophenotyping
and warrants further development.
Imaging mass cytometry (IMC) is an adaptation of mass
cytometry (CyTOF), a technique which has utilizes metal isotope
tags chelated to a polymers which are in turn conjugated to
monoclonal antibodies, which are ionized and then measured on
a single-cell basis using time of flight (TOF) mass spectrometry
(158, 162). The stable metal isotopes are derived from the
lanthanide series for a total of 37 unique metals, which can
be used in combination with non-lanthanide metals (bismuth,
gold, platinum) to create a panel of 40 markers which may
be simultaneously assessed. IMC involves the labeling of
immobilized tissues or cells on slides with mass cytometry
antibodies which are then ablated using a pulsed laser and
the resulting particles are transported to the mass cytometry
via a stream of inert gas (162). The metal isotopes are all
simultaneously detected and indexed for the specific location of
the spot and an image is generated using the ion current for
each mass tag to indicate the abundance of that tag (162). All
of the detected markers are co-registered in computer generated
images and advanced image analysis software is employed to
segment and classify individual cells (162). Thus far, IMC has
been applied to dissect the microenvironments of normal human
and murine tissues as well as cell signaling pathways (162). Recent
studies also reported the use of IMC on human FFPE tissues (LN,
Hodgkin lymphoma and colon cancer), demonstrating its utility
for providing multiparametric immune profiles of tumor tissue
including microenvironmental features such as TLS in colon
cancer, which were found to have high numbers of FOXP3+
Treg (163). As IMC does not involve fluorescence, issues such
as fluorescence spectral overlap and sample autofluorescence are
obviated (158, 162). However, there are certain limitations to
IMC, in particular, given that most mass cytometry antibodies are
optimized for single cell suspension and not FFPE tissue and that
image acquisition by laser is highly time intensive (1.5 mm2 in
2 h) (158, 162).
Co-detection by indexing (CODEX) is a multiplex
fluorescence-based imaging approach which utilizes
oligonucleotide conjugated antibodies (158, 164). Up to 50
antibodies can be assessed simultaneously and the sample
is stained with the entire array of oligonucleotide-tagged
antibodies (158). Each oligonucleotide is custom prepared
with a 5’ overhang which allows for the incorporation of a
fluorescent dye labeled nucleotide permitting the antibodies
which are to be detected first having shorter overhangs than
those which are set to be revealed later (158). A company which
is commercializing CODEX technology, Akoya Biosciences1,
has been established and offers an instrument which can be
integrated into existing fluorescent microscopes for assay
automation and image acquisition (165). While the technology
1https://www.akoyabio.com
offers several advantages such as obviating autofluorescence and
simultaneously assessing multiple markers, the methodology is
limited due to the sampling time and the fact that it has yet to
be optimized for FFPE tissue (158). Nevertheless, data have been
obtained for the application of CODEX in FFPE cancer tissues
including specialized image analysis pipelines (165). Both IMC
and CODEX have high potential for immunophenotyping of
the TME; however, optimization of the methodologies as well as
pipelines for the analysis and interpretation of the data obtained
from these multiplex technologies require significant further
investigation. Determining whether spatial configuration such
as the distance between various immune and non-immune cell
types, or the density of a specific TIL subset have association
with patient clinical parameters such as disease stage or survival
will be essential for revealing the translational value of these
technologies (158).
CONCLUDING REMARKS
A tumor’s capacity to evade immune control is now recognized
as a canonical “hallmark” of cancer (166). In this review,
we presented an overview of histopathological analysis of key
lymphocyte subsets in cutaneous melanoma. Moreover, we have
presented recent findings which offer tremendous potential
in improving TIL profiling both for routine pathology and
oncology research. A comprehensive classification of TIL in
H&E stained melanoma tissue has been available since 1989
(23). Furthermore, multiple lymphocyte subsets, in particular,
CD8+ T cells have shown both prognostic value for clinical
outcomes, as well as predictive value for response to ICB (12,
30, 125, 138). Nevertheless, in the absence of large multi-center
studies, standardized IHC protocols and automated enumeration
methods, it will be difficult to validate the potential of various
TIL subsets as prognostic and predictive biomarkers in cancer.
Furthermore, studies have shown that tumor associated myeloid
cells such as DC, macrophages, neutrophils and MDSC also
play vital roles in modulating lymphocyte recruitment to the
tumor (44, 167).
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